Read, pause, explore
Bremelanotide
Also listed as Vyleesi
A reference to read with the sources beside you.
Status as of . The reference fields below define the scope of these labels.
Filed under Sexual health for browsing.
Reference fields
Sources for these fields- Approval scope
- Vyleesi: eligible premenopausal women with distressing acquired generalized low-desire disorder.
- Route and formulation
- Subcutaneous injection.
- Mechanism
- Melanocortin-receptor agonist.
- Evidence
- Randomized trials.
- Limits of the evidence
- Exclude medical, relationship and drug causes; not performance enhancement.
- Safety context
- Uncontrolled hypertension or known cardiovascular disease: contraindicated.
A closer reading
Make space for the question
Turning a score into a label makes a result easier to summarize, but it can hide how close someone was to the dividing line. Hypothetical scores just above and just below a cutoff might receive different labels despite being nearby on the original scale. Meanwhile, people carrying the same label could have quite different scores. Reading both versions helps preserve that detail. The label describes a rule for grouping observations; the underlying scale shows distances that the rule leaves out. A useful interpretation should explain why that grouping serves the question rather than treating the boundary as self explanatory.
Keep these questions nearby
- How were the dividing line and the resulting category labels chosen?
- What differences become invisible when the original scores are replaced by labels?
- Would observations near the cutoff receive very different descriptions despite similar scores?
Sources
The references below accompany the entry as a whole. Dates show when each source was checked.
- VYLEESINLM · Checked
- Kingsberg trialsPubMed · Checked
Keep a little room for reading
Prepared by Healthy Pound Editorial Team. Educational reference; no clinical review is claimed. This page does not provide individual medical advice.